CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
批准 brexucabtagene autoleucel 用于治疗复发/难治性急性淋巴细胞白血病的成人患者
英文原题：Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
查看英文原题
Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2021年10月，brexucabtagene autoleucel成为首个获得美国食品药品监督管理局批准用于治疗复发/难治性B细胞急性淋巴细胞白血病成年患者的抗CD19CAR-T 细胞产品。该批准基于Zuma-3试验的结果，显著拓宽了该患者群体的治疗选择。本文中，我们回顾了该研究的结果及其意义。
展开英文摘要原文
In October 2021, brexucabtagene autoleucel became the first anti-CD19 chimeric antigen receptor T-cell product to receive approval from the Food and Drug Administration to treat adults with relapsed and refractory B-cell acute lymphoblastic leukemia. The approval is based on results from the Zuma-3 trial and significantly widens treatment options for this patient population. In this article, we review outcomes from this study and its implications.
论文信息
- 作者
- Frey NV
- 单位
- Cell Therapy and Transplant, Division of Hematology Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA.United States
- 文献类型
- 综述
- 期刊
- Blood2022 Jul 7
- 原文标识
- PubMed 35507688 · DOI 10.1182/blood.2021014892